Pfizer Inc. (PFE)
Should You Buy Pfizer Stock Right Now in 2025?
Pfizer (PFE 0.20%) is an interesting healthcare company with excellent prospects for cash flow growth.
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
Pfizer's PFE stock has risen 5.6% in the past month. This was due to the company's encouraging guidance for 2025 issued in mid-December 2025.
The Zacks Analyst Blog Berkshire Hathaway, The Home Depot, Pfizer and AMREP
Berkshire Hathaway, The Home Depot, Pfizer and AMREP are included in this Analyst Blog.
Pfizer (PFE) Advances While Market Declines: Some Information for Investors
In the latest trading session, Pfizer (PFE) closed at $26.61, marking a +0.3% move from the previous day.
Here's Why Pfizer (PFE) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pfizer's 2025 Comeback: What's Driving Growth
Pfizer targets $4 billion in operational savings by 2024, improving margins and driving long-term profitability. PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 billion through balance sheet optimization. Investing $10.7-$11.7 billion in R&D, focusing on obesity treatments, oncology, and vaccines to address unmet needs.
Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact
The small-cap won't receive an expected payout in the first quarter, creating a cash overhang.
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
Sangamo Therapeutics (SGMO) shares cratered more than 50% Tuesday, a day after the biopharma firm announced that Pfizer (PFE) had pulled out of its deal to co-develop a hemophilia drug.
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc PFE.
3 Reasons to Buy Pfizer Stock Like There's No Tomorrow
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents protecting their proprietary drugs expire.
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. NYSE: PFE stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something causes shares to slide right back down.
Sangamo Therapeutics down 50% premarket on Pfizer blow
Shares in Sangamo Therapeutics dropped 50% premarket after Pfizer Inc (NYSE:PFE, ETR:PFE) ended its collaboration on a gene therapy for haemophilia The drug, giroctocogene fitelparvovec, met its target in a late-stage trial, with Pfizer previously expected to seek regulatory approval in 2025. “We were extremely surprised and very disappointed,” said Sangamo's CEO, Sandy Macrae.
